✦ LIBER ✦

The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research

✍ Scribed by Janneke P.C. Grutters; Madelon Pijls-Johannesma; Dirk De Ruysscher; Andrea Peeters; Stefan Reimoser; Johan L. Severens; Philippe Lambin; Manuela A. Joore

Book ID: 116395488
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 511 KB
Volume: 36
Category: Article
ISSN: 0305-7372
DOI: 10.1016/j.ctrv.2010.02.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMD19 COST-EFFECTIVENESS OF EPIDERMAL GR

PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO

✍ W. Chen; P. Ellis; L. Levin; M. Krahn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

PCN114 COST-EFFECTIVENESS ANALYSIS OF PE

PCN114 COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY: RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION

✍ L Guidi; S Malik; D Valle; Y Asukai; K Taipale 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN43 THE COST OF TREATING GRADE 3/4 ADV

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

✍ C Chouaid; A Vergnenegre; M Brunner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Paclitaxel plus cisplatin is as effectiv

Paclitaxel plus cisplatin is as effective as regimens containing gemcitabine in people with advanced non-small cell lung cancer: Abstracted from: Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909–17.

✍ Sarah Danson 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 163 KB